



# DIA

## Regulatory Submissions, Information, and Document Management Forum

February 12-14  
North Bethesda, MD

# FDA eCTD v4 Implementation Update

Jonathan Resnick, Business Informatics Specialist, CDER/OSP/OBI

# Disclaimer

The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to DIA, its directors, officers, employees, volunteers, members, chapters, councils, Communities or affiliates.

This presentation is incomplete without accompanying verbal commentary.

# Disclaimer

The views and opinions presented here represent those of the speakers and should not be considered to represent advice or guidance on behalf of the U.S. Food and Drug Administration.

# Agenda

- ICH Activities
- FDA Activities
- FDA Implementation Strategy
- Technical Pilot
- Technical Feedback on eCTD v4.0 Samples
- How to Prepare



# ICH Activities



# ICH Activities

- ICH eCTD v4.0 Implementation Package
  - V1.5 May 2022
- Q&A Change Requests
  - V1.7 June 2022
- Regional Implementation Information posted on ICH eCTD v4.0 webpage
  - Regional planned Technical Pilots & Implementation Dates
  - Links to regional Implementation Documents



Keep an eye on this space. ICH updates expected soon.



Region	Technical Pilot <sup>1</sup>	Implementation Dates <sup>2</sup>	Implementation Documents
ANVISA, Brazil	4Q 2024 (Planned)	1Q 2025 (Production Pilot) 2025 (Voluntary)	TBD
EC, Europe	2024 CAPs (Planned)	2025 (Voluntary for CAPs) 2026 (Voluntary for MRP/DCP/NP) 2027 (Mandatory for CAPs) TBC (Mandatory for MRP/DCP/NP)	<a href="#">EC, Europe regional implementation page</a>
FDA, United States	2022 - 2Q 2023 (Completed)	2024 (Voluntary) 2029 (Mandatory)	<a href="#">FDA, United States regional implementation page</a>
Health Canada, Canada	2024 (Planned)	2025 (Voluntary) 2027 (Mandatory)	<a href="#">Health Canada, Canada regional implementation page</a>
MFDS, Republic of Korea	TBD	2025 (Voluntary) 2029 (Mandatory)	TBD
MHLW/PMDA, Japan	2Q 2021 (Completed)	2022 (Voluntary) 2026 (Mandatory)	<a href="#">MHLW/PMDA, Japan regional implementation page</a>
Swissmedic, Switzerland	2024 (Planned)	2025 (Voluntary) 2029 (Mandatory)	<a href="#">Swissmedic, Switzerland regional implementation page</a>
TGA, Australia	4Q 2024 (Planned)	2025 (Voluntary) TBD (Mandatory)	2023 (In Progress)

*This information will be updated biannually based on the progress of ongoing implementation activities.*

**[Updated in July 2023]**

# FDA Activities



# FDA Activities

- eCTD v4.0 Technical Conformance Guide and FDA eCTD v4.0 Module 1 Implementation Package
  - Posted February 2020 for public comment
  - Posted updates on September 2022
- Specifications for eCTD v4.0 Validation Criteria (October 2022)
- eCTD v4.0 Comprehensive Table of Contents Headings and Hierarchy (June 2021)
- Software updates and testing
  - Currently testing eCTD v4.0 vendor software
  - eCTD v4.0 Technical Pilot



Keep an eye on this space. FDA updates expected soon.



# FDA Implementation Strategy

# FDA Implementation Strategy

- Initial release/acceptance for new applications in eCTD v4.0
  - Allows for development of eCTD v4.0 applications across regions
  - Completed testing with industry in 2023
  - Begin accepting\* new applications in eCTD v4.0 in FY24
  - Provide feedback on sample eCTD v4 submissions
- Future phases
  - Transition of current applications (Forward Compatibility)
  - Two-way communication

\*When FDA is ready to accept eCTD v4, the agency will update the FDA Data Standards Catalog to reflect the date support begins

<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/data-standards-catalog>



## Electronic Common Technical Document (eCTD) v4.0

*The documents and files referenced on this web page are: FOR IMPLEMENTATION PLANNING ONLY*



The documentation and links on this webpage provide information on how to submit eCTD v4.0-based electronic submissions to the Center for Drug Evaluation and Research (CDER) or the Center for Biologics Evaluation and Research (CBER).

### FDA eCTD v4.0 Implementation Status

CDER and CBER are in the process of testing our eCTD v4.0 software.

CDER and CBER plan to accept new applications in eCTD v4.0 format in 2024. Future implementation phases will address existing v3.2.2 applications and two-way communication.

# Technical Pilot

# Technical Pilot

- The objective of this testing was to determine if the implementation satisfied the requirements in the technical specification and make any changes prior to accepting eCTD v4.0 submissions in the production environment.
- Duration (June 2022 – April 30, 2023)
- Technical Pilot Scope
  - Submission Scope
    - ✓ Original eCTD v4.0 applications and subsequent submissions (e.g., amendments, supplements)
    - Grouped eCTD v4.0 submissions
  - Enhancement Scope
    - ✓ Life-cycle (one-to-one, one-to-many, many-to-one)
    - ✓ Document reuse
    - ✓ Document ordering
    - ✓ Keyword modifications
    - ✓ “Group Title” Keyword



# Technical Feedback on eCTD v4.0 Samples

# Opportunity to obtain technical feedback on sample eCTD v4.0 submissions



- Exists today for eCTD v3.2.2
  - Find information about it here: <https://www.fda.gov/drugs/electronic-regulatory-submission-and-review/submit-ectd-or-standardized-data-sample-fda>
- CDER plans to expand to include v4.0
  - Will commence when FDA begins accepting voluntary eCTD v4.0 submissions or possibly earlier. Check above link to updates.
- FDA CDER eSub team performs technical validation on the sample submission and reports back on validation errors and other technical issues





# eCTD v4.0 Update – How to Prepare

# How to Prepare

- Discuss eCTD v4.0 development plans with your vendor and/or IT organization
  - Understanding the specifications
  - Is there a plan for transitioning to eCTD v4.0?
  - Send questions to ICH or FDA
- Become familiar with eCTD v4.0 concepts and enhancements
  - ICH Supplemental Documents for eCTD v4.0
    - Support Documentation for eCTD v4.0 Implementation Package - Explains contents enclosed in the Implementation Package. The target audience is business and technical personnel who build and/or review the eCTD v4.0 XML Messages.
    - Orientation Material for eCTD v4.0 Implementation Package - Provides an outline of eCTD v4.0 concepts from business perspective. The target audience is business personnel and management involved in any aspect of eCTD submission design and preparation.
  - FDA eCTD v4.0 Technical Conformance Guide
- Know where to find the eCTD v4.0 information



# eCTD V4.0 Websites



- ICH eCTD v4.0 Webpage (<https://www.ich.org/page/ich-electronic-common-technical-document-ectd-v40>)
  - ICH eCTD v4.0 Implementation Package
  - Supplemental Documents for eCTD v4.0 Implementation Package
  - Regional Implementation Information & Regional Links
  - Change Control
    - Process
    - Change Requests & Questions
    - Q&A document
  
- FDA eCTD v4.0 Webpage (<https://www.fda.gov/drugs/electronic-regulatory-submission-and-review/electronic-common-technical-document-ectd-v40>)
  - FDA eCTD v4.0 M1 Implementation Package
  - eCTD v4.0 Technical Conformance Guide
  - Link to ICH eCTD v4.0 webpage



Keep an eye on the ICH and FDA sites above. Updates expected within next few months.



# Questions?

DIA